Michelle Hill
Containment Level 3 Manager
Michelle has been appointed to manage the 600 square metre containment level 3 facilities in the, currently under construction, Cyrus Poonawalla Vaccines Research Building (P2B). The building is due to be completed in April 2028.
She has been a member of the University for 15 years, starting as a Research Assistant and Laboratory manager in the Biochemistry department conducting research into the antiviral effects of immunosugars on a range of viruses including dengue, HCV, Zika and Sars CoV 2, before moving to the Sir William Dunn School of Pathology to become the containment level 3 Facility manager and Lab manager for the James and Lillian Martin centre for Stem Cell Research.
Recent publications
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals
Journal article
Brun J. et al, (2025), Antiviral Research, 237, 106123 - 106123
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition
Journal article
Asor R. et al, (2024), Proceedings of the National Academy of Sciences, 121
Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses
Journal article
Hills RA. et al, (2024), Nature Nanotechnology, 19, 1216 - 1223
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2
Journal article
Cornish K. et al, (2024), Open Biology, 14
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Journal article
Arman BY. et al, (2023), International Journal of Molecular Sciences, 25, 354 - 354